TITLE

GERON REGAINS RIGHTS FOR TELOMERASE INHIBITORS

PUB. DATE
March 2001
SOURCE
Worldwide Biotech;Mar2001, Vol. 13 Issue 3, p3
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
Reports that Geron Corporation regained all rights to its telomerase inhibitors from Pharmacia Corporation as of March 2001.
ACCESSION #
4155588

 

Related Articles

  • GERON GRANTED U.S. PATENT FOR EMBRYONIC GERM CELLS.  // Biotech Business;Feb2002, Vol. 15 Issue 2, p5 

    No abstract available.

  • Lighting the fuse on tumour cells. Coghlan, Andy // New Scientist;11/27/93, Vol. 140 Issue 1901, p18 

    Reports on Geron's discovery of a compound making cancer cells mortal in a test tube. Linking biochemical changes gicing the cancer cells immortality to one regulating ageing; Discovery of the clock mechanism residing in the cell's DNA; Discovered compound as stopping the tumor cells' division.

  • Researching Immortality. Larson, Ruth // Insight on the News;02/08/99, Vol. 15 Issue 5, p40 

    Reports on the discovery of the telomerase as an antiaging enzyme. How the enzyme works; Right granted to Geron Corp. to commercialize the technique; Study conducted by Geron on several possible gene-therapy applications of the technique.

  • Geron to Webcast Analyst and Investor Meeting on Company's Oncology Programs on March 29 2011.  // Biomedical Market Newsletter;4/30/2011, p503 

    A webcast about the analyst and investor meeting on the oncology programs of Geron Corp. to be held on March 29, 2011 in New York is discussed.

  • HESC-DERIVED HEMATOPOIETIC CELLS PREVENT IMMUNE REJECTION.  // Biotech Business;Mar2003, Vol. 16 Issue 3, p2 

    Provides information on data announced by Geron Corp. that advance the promise of cell therapies based upon human embryonic stem cells in 2003.

  • Landmark Stem Cell Trials Begin.  // New Mobility;Jan2011, Vol. 22 Issue 208, p11 

    The article reports on the start of the first round in a series of clinical trials of a therapy developed by Geron Corp. involving human embryonic stem cells, announced by researchers in October 2010.

  • Financings Roundup.  // BioWorld Today;12/10/2010, Vol. 21 Issue 238, p4 

    The article reports that underwriters of Geron Corp. have exercised their option in full to purchase 2,608,695 additional shares of the company's common stock at 5 U.S. dollars per share, with expected gross proceeds of 100 million U.S. dollars.

  • Financings Roundup.  // BioWorld Today;12/14/2010, Vol. 21 Issue 240, p7 

    The article reports on a public offering of common stock closed by Geron Corp. of Menlo Park, California.

  • Financings roundup. Sheridan, Cormac // BioWorld Today;2/6/2014, Vol. 25 Issue 25, p12 

    The article reports on the expected 96.7-million-dollar net proceeds at the close of the public offering of pharmaceutical firm Geron Corp. in California as of February 6, 2014.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics